Cargando…

CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide

There is a strong biological rationale for the augmentation of allogeneic natural killer (NK) cell therapies with a chimeric antigen receptor (CAR) to enhance acute myeloid leukemia (AML) targeting. CD38 is an established immunotherapeutic target in multiple myeloma and under investigation as a targ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gurney, Mark, Stikvoort, Arwen, Nolan, Emma, Kirkham-McCarthy, Lucy, Khoruzhenko, Stanislav, Shivakumar, Rama, Zweegman, Sonja, van de Donk, Niels W.C.J., Mutis, Tuna, Szegezdi, Eva, Sarkar, Subhashis, O’Dwyer, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804573/ https://www.ncbi.nlm.nih.gov/pubmed/33375774 http://dx.doi.org/10.3324/haematol.2020.271908

Ejemplares similares

CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an “Off the Shelf” Therapy for Multiple Myeloma
por: Stikvoort, Arwen, et al.
Publicado: (2021)

Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant
por: Holthof, Lisa C., et al.
Publicado: (2021)

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
por: Verkleij, Christie P. M., et al.
Publicado: (2020)

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
por: Drent, Esther, et al.
Publicado: (2015)

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
por: Frerichs, Kristine A., et al.
Publicado: (2019)

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
por: van de Donk, Niels W.C.J., et al.
Publicado: (2018)

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
por: Poels, Renée, et al.
Publicado: (2021)

P808: CONTROLLED FRATRICIDE TO AUGMENT ANTI-MYELOMA REACTIVITY OF SLAMF7 AND CD38 CAR T CELLS
por: Konetzki, Verena, et al.
Publicado: (2023)

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
por: van de Donk, Niels W. C. J., et al.
Publicado: (2016)

Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity
por: Hiemstra, Ida H., et al.
Publicado: (2023)

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
por: Drent, Esther, et al.
Publicado: (2018)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
por: Plesner, Torben, et al.
Publicado: (2020)

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
por: Franssen, Laurens E., et al.
Publicado: (2020)

Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma
por: Kinder, Michelle, et al.
Publicado: (2021)

CD38 as a pan-hematologic target for chimeric antigen receptor T cells
por: Glisovic-Aplenc, Tina, et al.
Publicado: (2023)

CD38 in Neurodegeneration and Neuroinflammation
por: Guerreiro, Serge, et al.
Publicado: (2020)

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
por: Roccatello, Dario, et al.
Publicado: (2020)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

The role of CD38 in HIV infection
por: Lu, Liqi, et al.
Publicado: (2021)

CD38 in Advanced Prostate Cancers
por: Guo, Christina, et al.
Publicado: (2021)

Targeting CD38 for acute leukemia
por: Zhong, Xushu, et al.
Publicado: (2022)

All-trans retinoic acid and interferon-α increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors
por: Mihara, K, et al.
Publicado: (2016)

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
por: Chemlal, Djamila, et al.
Publicado: (2023)

Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma
por: Li, Xiaorui, et al.
Publicado: (2021)

CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
por: Radhakrishnan, Sabarinath V., et al.
Publicado: (2020)

Interferon gamma selectively inhibits very primitive CD342+CD38- and not more mature CD34+CD38+ human hematopoietic progenitor cells
Publicado: (1994)

Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
por: Zannetti, Beatrice Anna, et al.
Publicado: (2020)

Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma
por: Feng, Yaru, et al.
Publicado: (2021)

CD38: T Cell Immuno-Metabolic Modulator
por: Kar, Anwesha, et al.
Publicado: (2020)

Roles of CD38 in the Immune Response to Infection
por: Glaría, Estibaliz, et al.
Publicado: (2020)

CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity
por: Piedra-Quintero, Zayda L., et al.
Publicado: (2020)

T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells
por: Mihara, Keichiro, et al.
Publicado: (2017)

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo
por: Fumey, William, et al.
Publicado: (2017)

CD38, CD157, and RAGE as Molecular Determinants for Social Behavior
por: Higashida, Haruhiro, et al.
Publicado: (2019)

A descriptive study of fratricide in tunisia
por: Guermazi, A., et al.
Publicado: (2021)

Decreased levels of T follicular helper (CD4+CXCR5+) cells and CD27+CD38+ and CD27+CD38− B cells in ankylosing spondylitis patients correlate with markers of inflammation
por: Lejon, Kristina, et al.
Publicado: (2022)

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
por: Costa, Federica, et al.
Publicado: (2017)

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma
por: Fayon, Maxime, et al.
Publicado: (2021)

CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells
por: Liao, Chan, et al.
Publicado: (2023)

Responses of CD27(+)CD38(+) plasmablasts, and CD24(hi)CD27(hi) and CD24(hi)CD38(hi) regulatory B cells during primary dengue virus 2 infection
por: Lei, Chenshuang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vi9v3egode9hkhihiktf9obui6